港股异动 | 复宏汉霖(02696)涨超4% 汉利康®新增两项适应症获批 7款创新管线将亮相AACR大会

智通财经
Apr 10

智通财经APP获悉,复宏汉霖(02696)涨超4%,截至发稿,涨4.44%,报83.55港元,成交额8776.22万港元。

消息面上,4月9日,复宏汉霖宣布,公司自主开发和生产的汉利康®(利妥昔单抗)用于非霍奇金淋巴瘤下的两项新增适应症的补充申请获国家药品监督管理局(NMPA)批准。作为中国首个生物类似药,汉利康®已全面覆盖原研利妥昔单抗在国内获批上市的全部适应症,包括非霍奇金淋巴瘤、慢性淋巴细胞白血病,以及原研未在华获批的类风湿关节炎,成为国内获批适应症数量最多的利妥昔单抗。

值得关注的是,美国癌症研究协会年会(AACR 2026)将于2026年4月17日至22日在美国圣地亚哥举行。本届AACR大会上,复宏汉霖将围绕HLX43(PD-L1 ADC)、HLX316(B7-H3×唾液酸酶融合蛋白)、HLX3902(STEAP1×CD3×CD28三特异性TCE)及依托Hanjugator™等自主平台开发的多款新型ADC(EGFRxcMET双抗ADC HLX48、HER2双表位ADC HLX49、ADAM9 ADC HLX402、ALPP/ALPPL2 ADC HLX85),集中展示7款具有“同类首创”或“同类最优”潜力的早期创新资产。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10